Patents by Inventor Neelakantan Balasubramanian

Neelakantan Balasubramanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tyrosine kinase inhibitors
    Patent number: 7223757
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Topoisomerase inhibitors
    Patent number: 7138377
    Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: November 21, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Edward H. Ruediger, Neelakantan Balasubramanian, Mikael Mahler, Carol Bachand, Francis Beaulieu
  • Tyrosine kinase inhibitors
    Patent number: 7081454
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: July 25, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Novel tyrosine kinase inhibitors
    Publication number: 20060079518
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Application
    Filed: November 30, 2005
    Publication date: April 13, 2006
    Inventors: Mark Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark Saulnier, Peiying Liu, Xiaopeng Sang, David Frennesson, Karen Stoffan, James Tarrant, Anne Marinier, Stephan Roy
  • Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors
    Patent number: 6924391
    Abstract: Inhibitors of the cytosolic phospholypase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula wherein X, Z, X1, R1, R2, Ra, Rb, R3, R4 and Y are as defined in the specification.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: August 2, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jacques Banville, Roger Remillard, Neelakantan Balasubramanian, Gilles Bouthillier, Alain Martel
  • Novel tyrosine kinase inhibitors
    Publication number: 20040044203
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: October 2, 2002
    Publication date: March 4, 2004
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Anhydro sugar derivatives of indolocarbazoles
    Patent number: 6686385
    Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
    Type: Grant
    Filed: May 7, 2003
    Date of Patent: February 3, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark G. Saulnier, Edward H. Ruediger, Neelakantan Balasubramanian, David Bertil Frennesson, Mikael Mahler, Kurt Zimmermann
  • Topoisomerase inhibitors
    Patent number: 6677450
    Abstract: The present invention relates to novel N12, N13-bridged sugar derivatives of indolylopyrrolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: January 13, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark G. Saulnier, Edward H. Ruediger, Neelakantan Balasubramanian, Mikael Mahler, Francis Beaulieu, Carol Bachand, David B. Frennesson
  • ANHYDRO SUGAR DERIVATIVES OF INDOLOCARBAZOLES
    Publication number: 20030220387
    Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
    Type: Application
    Filed: May 7, 2003
    Publication date: November 27, 2003
    Applicant: Bristol-Myers Squibb Company
    Inventors: Mark G. Saulnier, Edward H. Ruediger, Neelakantan Balasubramanian, David Bertil Frennesson, Mikael Mahler, Kurt Zimmermann
  • Tumor proliferation inhibitors
    Patent number: 6653290
    Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
    Type: Grant
    Filed: September 25, 2001
    Date of Patent: November 25, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Edward H. Ruediger, Neelakantan Balasubramanian, Mikael Mahler, Carol Bachand, Francis Beaulieu
  • Topoisomerase inhibitors
    Publication number: 20030203860
    Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
    Type: Application
    Filed: May 9, 2003
    Publication date: October 30, 2003
    Applicant: Bristol-Myers Squibb Company
    Inventors: Edward H. Ruediger, Neelakantan Balasubramanian, Mikael Mahler, Carol Bachand, Francis Beaulieu
  • Anhydro sugar derivatives of indolocarbazoles
    Patent number: 6610727
    Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-1 activity and are useful in inhibiting the proliferation of tumor cells.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: August 26, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark G. Saulnier, Edward H. Ruediger, Neelakantan Balasubramanian, David Bertil Frennesson, Mikael Mahler, Kurt Zimmermann
  • Alpha-substituted thio, -oxo trifluoromethylketones as phospholipase inhibitors
    Patent number: 6492550
    Abstract: Inhibitors of the cytosolic phospholypase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula where X, Z, X1, R1, R2, Ra and Rb are as defined in the specification.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: December 10, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jacques Banville, Serge Plamondon, Yonghua Gai, Neelakantan Balasubramanian
  • Thio derivatives of sordarin as antifungal agents
    Patent number: 6436930
    Abstract: The present invention relates to antifungal compounds having the structural formula: and pharmaceutically acceptable salts, solvates and prodrugs thereof. The present invention further relates to pharmaceutical compositions containing said compound, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use in the treatment of a fungal infection in an animal host.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: August 20, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Serrano-Wu, Xuhua Du, Neelakantan Balasubramanian, Denis R. St. Laurent
  • Anhydro sugar derivatives of indolocarbazoles
    Publication number: 20020111375
    Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
    Type: Application
    Filed: September 27, 2001
    Publication date: August 15, 2002
    Inventors: Mark G. Saulnier, Edward H. Ruediger, Neelakantan Balasubramanian, David Bertil Frennesson, Mikael Mahler, Kurt Zimmermann
  • Topoisomerase inhibitors
    Publication number: 20020107237
    Abstract: The present invention relates to novel N12, N13-bridged sugar derivatives of indolylopyrrolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
    Type: Application
    Filed: September 27, 2001
    Publication date: August 8, 2002
    Inventors: Mark G. Saulnier, Edward H. Ruediger, Neelakantan Balasubramanian, Mikael Mahler, Francis Beaulieu, Carol Bachand, David B. Frennesson
  • Alpha-and beta-substituted trifluoromethyl ketones as phospholipase inhibitors
    Patent number: 6414179
    Abstract: Inhibitors of the cytosolic phospholipase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula where X, Z, R1, R2, R3, R4, Ra and Rb are as defined in the specification.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: July 2, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jacques Banville, Anne Marinier, Yonghua Gai, Serge Plamondon, Stephan Roy, Neelakantan Balasubramanian
  • Tumor proliferation inhibitors
    Publication number: 20020068705
    Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
    Type: Application
    Filed: September 25, 2001
    Publication date: June 6, 2002
    Inventors: Edward H. Ruediger, Neelakantan Balasubramanian, Mikael Mahler, Carol Bachand, Francis Beaulieu
  • Alpha-substituted thio,-oxo trifluoromethylketones as phospholipase inhibitors
    Publication number: 20020068722
    Abstract: Inhibitors of the cytosolic phospholypase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases.
    Type: Application
    Filed: February 8, 2001
    Publication date: June 6, 2002
    Inventors: Jacques Banville, Serge Plamondon, Yonghua Gai, Neelakantan Balasubramanian
  • Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors
    Publication number: 20020065246
    Abstract: Inhibitors of the cytosolic phospholipase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases.
    Type: Application
    Filed: March 23, 2001
    Publication date: May 30, 2002
    Inventors: Jacques Banville, Anne Marinier, Yonghua Gai, Serge Plamondon, Stephan Roy, Neelakantan Balasubramanian